CancerDrs

Lymphoma clinical trials in Wisconsin

31 actively recruiting lymphoma trials at 50 sites across Wisconsin.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Wisconsin:
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • Aurora Saint Luke's South Shore — Cudahy, Wisconsin
  • Aurora Health Care Germantown Health Center — Germantown, Wisconsin
  • Aurora Cancer Care-Grafton — Grafton, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Wisconsin:
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • William S Middleton VA Medical Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …

Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Wisconsin:
  • Research Site — Madison, Wisconsin
  • Research Site — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Wisconsin:
  • SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048) — Madison, Wisconsin
  • University Hospital and UW Health Clinics ( Site 0006) — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in Wisconsin:
  • Prohealth Care Inc — Waukesha, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Wisconsin:
  • University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423) — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Aurora Health Care Germantown Health Center — Germantown, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in Wisconsin:
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…

Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in Wisconsin:
  • Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignan…

Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell N…

Sponsor: Imugene Limited
NCT ID: NCT03666000
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Sponsor: Schrödinger, Inc.
NCT ID: NCT05544019
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolesce…

Sponsor: New York Medical College
NCT ID: NCT04972942
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

Sponsor: Orca Biosystems, Inc.
NCT ID: NCT03802695
Sites in Wisconsin:
  • Froedtert Memorial Lutheran Hospital — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cel…

Sponsor: Marker Therapeutics, Inc.
NCT ID: NCT05798897
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that hav…

Sponsor: Medical College of Wisconsin
NCT ID: NCT05990465
Sites in Wisconsin:
  • Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Wisconsin:
  • Aspirus Langlade Hospital — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Ascension Saint Elizabeth Hospital — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
View on ClinicalTrials.gov →
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Wisconsin:
  • University of Wisconsin - Madison — Madison, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →

Showing 25 of 31 trials with sites in Wisconsin. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07